Willy Ssengooba
Universiteit van Amsterdam
H-index: 25
Europe-Netherlands
Top articles of Willy Ssengooba
A Global Tuberculosis Dictionary: unified terms and definitions for the field of tuberculosis
The Lancet Global Health
2024/5/1
Leonardo Martinez
H-Index: 17
Willy Ssengooba
H-Index: 19
Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of …
The Lancet Microbe
2024/4/1
A stool based qPCR for the diagnosis of TB in children and people living with HIV in Uganda, Eswatini and Mozambique (Stool4TB): a protocol for a multicenter diagnostic evaluation
BMC Infectious Diseases
2024/2/21
Willy Ssengooba
H-Index: 19
Christoph Lange
H-Index: 40
Performance evaluation of Truenat MTB and Truenat MTB-RIF DX assays in comparison to gene XPERT MTB/RIF ultra for the diagnosis of pulmonary tuberculosis in Uganda
BMC Infectious Diseases
2024/2/13
Willy Ssengooba
H-Index: 19
Effect of mixed Mycobacterium tuberculosis infection on rapid molecular diagnostics among patients starting MDR-TB treatment in Uganda
BMC Infectious Diseases
2024/1/10
Willy Ssengooba
H-Index: 19
Predisposing, enabling, and need factors influencing rapid uptake of the World Health Organization endorsed TB diagnostic technologies in Africa.
medRxiv
2024
Anandi Martin
H-Index: 24
Willy Ssengooba
H-Index: 19
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials
The Lancet Microbe
2023/11/1
Identification of potential novel combination antibiotic regimens based on drug-susceptibility and genetic diversity of Gram-negative bacteria causing neonatal sepsis in low …
2023/10/24
Geographic distribution and predictors of diagnostic delays among possible TB patients in Uganda
Public Health Action
2023/9/21
Evaluation of Xpert MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda
Plos one
2023/8/17
Willy Ssengooba
H-Index: 19
Lots of considerations when evaluating the FujiLAM assay
The Lancet Global Health
2023/4/1
Willy Ssengooba
H-Index: 19
Two new compounds and the anti-mycobacterial activity of the constituents from Zanthoxylum leprieurii root bark
Phytochemistry Letters
2023/4/1
Matthias Heydenreich
H-Index: 20
Willy Ssengooba
H-Index: 19
Second-line drug resistance markers as proxy indicators of time to sputum culture conversion among second-line drug resistant tuberculosis patients tested in Uganda: A cross …
F1000Research
2023/1/16
Willy Ssengooba
H-Index: 19
Seungmo Kim
H-Index: 9
PA-755 Feasibility and acceptability of stool-based TB diagnosis: perspectives from healthcare providers in Manhiça district, southern Mozambique
2023/12/1
PA-583 Revolutionising tuberculosis treatment response monitoring and developing research capacity in Africa: progress and potential of the tuberculosis molecular bacterial …
2023/12/1
PA-522 Performance of alternative bacteriological measures of response to MDR-TB therapy during the initial 16 weeks of treatment
2023/12/1
Willy Ssengooba
H-Index: 19
Wilber Sabiiti
H-Index: 8
Prevalence and Risk Factors of Rifampicin Resistant Mycobacterium Tuberculosis among Human Immune Virus Sero-Positive Patients in South Western Uganda
2023/11/15
Willy Ssengooba
H-Index: 19
Cardiovascular risk factors among people with drug-resistant tuberculosis in Uganda
BMC Cardiovascular Disorders
2022/11/4
Willy Ssengooba
H-Index: 19
Ronald Olum
H-Index: 4
Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment
The International Journal of Tuberculosis and Lung Disease
2022/11/1
Prevalence and antimicrobial resistance profiles of Neisseria gonorrhea and Chlamydia trachomatis isolated from individuals attending STD clinics in Kampala, Uganda
African Health Sciences
2022/10/27
Co-Authors
